Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7269624 | 0.94 | ADORA2A (0.88) | ADORA2AADORA2BADORA1MEN1GMNN | |
| SCHEMBL30082250 | 0.92 | ADORA2A (0.86) | ADORA2AADORA2B | |
| SCHEMBL7269959 | 0.89 | ADORA2A (0.80) | ADORA2AADORA2B | |
| SCHEMBL8396163 | 0.86 | ADORA2B (0.74) | ADORA2AADORA2BADORA1 | |
| SCHEMBL8395066 | 0.86 | ADORA2B (0.74) | ADORA2AADORA2BADORA1 | |
| SCHEMBL7269734 | 0.85 | ADORA2A (0.73) | ADORA2AADORA2BADORA1 | |
| SCHEMBL7277196 | 0.83 | ADORA2A (0.71) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL9427714 | 0.82 | ADORA2A (0.69) | ADORA2AADORA2BADORA1 | |
| SCHEMBL7268434 | 0.81 | ADORA2A (0.68) | ADORA2AADORA2B | |
| SCHEMBL7274376 | 0.81 | ADORA2A (0.68) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9555037-B2 | Method of using vasoconstrictive agents during energy-based tissue therapy | COVIDIEN AG | 2017-01-31 | — | — | US | claimed |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | SHERWOOD SERVICES AG (CH) | 2016-06-02 | — | — | US | claimed |
| US-8202242-B2 | Method of using vasoconstrictive agents during energy-based tissue therapy | COVIDIEN AG (CH) | 2012-06-19 | — | — | US | claimed |
| US-20110189255-A1 | DRUG-ELUTING STENTS FOR ADENOSINE RECEPTOR MODULATION | PURDUE RESEARCH FOUNDATION | 2011-08-04 | — | — | US | claimed |
| US-7767686-B2 | Method of using adenosine receptor blockers during tissue ablation | COVIDIEN AG (CH) | 2010-08-03 | — | — | US | claimed |
| US-20080275068-A1 | administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone | COVIDIEN AG (CH) | 2008-11-06 | — | — | US | claimed |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | claimed |
| US-20070208042-A1 | Method of using vasoconstrictive agents during energy-based tissue therapy | SHERWOOD SERVICES AG | 2007-09-06 | — | — | US | claimed |
| EP-1014995-A4 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | ADERIS PHARMACEUTICALS INC (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040259889-A1 | Methods of treating pulmonary disease | BIOGEN IDEC MA INC. | 2004-12-23 | — | — | US | claimed |
| JP-2002505687-A | — | — | 2002-02-19 | — | — | JP | claimed |
| US-6339072-B2 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS INC. | 2002-01-15 | — | — | US | claimed |
| US-20010009907-A1 | Compositions and methods for preventing restenosis following revascularization procedures | DISCOVERY THERAPEUTICS, INC. | 2001-07-26 | — | — | US | claimed |
| EP-1014995-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | Discovery Therapeutics, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0970696-A1 | Combination of loop diuretics with adenosine A1-receptor antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-01-12 | — | — | EP | claimed |
| WO-1998057651-A1 | COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES | DISCOVERY THERAPEUTICS, INC. (US) | 1998-12-23 | — | — | WO | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| EP-0386675-B1 | Xanthine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1996-06-05 | — | — | EP | claimed |
| US-5068236-A | Diuretics, renal protective agents and hypotensives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-11-26 | — | — | US | claimed |
| EP-0386675-A2 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-09-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259889-A1 | Methods of treating pulmonary disease | ADORA1, ADORA2A, TBXA2R | ADORA2A 2/4885ADORA2B 5/4885ADORA1 1/4885 |
| US-20070207979-A1 | Method of using adenosine receptor blockers during tissue ablation | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA2B 2/4885ADORA1 4/4885 |
| US-20070208042-A1 | Method of using vasoconstrictive agents during energy-based tissue therapy | PLAT, TEK, PLG | ADORA2A 271/4885ADORA2B 339/4885ADORA1 503/4885 |
| US-20160151374-A1 | METHOD OF USING VASOCONSTRICTIVE AGENTS DURING ENERGY-BASED TISSUE THERAPY | PLAT, TEK, PLG | ADORA2A 271/4885ADORA2B 339/4885ADORA1 503/4885 |
| US-20080275068-A1 | administering a vasoconstrictive agent such as an adenosine receptor antagonist ( 1,3-dipropyl-8-cyclopentylxanthine, 8-(3-Chlorostyryl)caffeine, 6-carboxy-methyl-5,9-dihydro-9-methyl-2-phenyl-[1,2,4]-triazolo[5,1-a][2,7]naphthyridine) to the mammal to increases the size of the coagulation zone | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.